Comparative Pharmacology
Head-to-head clinical analysis: SULSTER versus UROPLUS SS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULSTER versus UROPLUS SS.
SULSTER vs UROPLUS SS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulster is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thus bacterial DNA replication.
Uroplus SS contains sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid (PABA) for dihydropteroate synthase. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. The sequential blockade of folic acid metabolism produces bactericidal activity.
2.5 mg orally twice daily.
4 grams orally once daily as a single dose or in divided doses for 10 to 14 days for urinary tract infections.
None Documented
None Documented
Terminal half-life 3.5-4.5 hours in normal renal function; prolonged to 10-15 hours with creatinine clearance <30 mL/min.
Terminal elimination half-life is 18–24 hours, allowing once-daily dosing; steady-state achieved in 3–5 days.
Primarily renal (60-70% unchanged), with 20-30% as glucuronide conjugate; biliary/fecal <10%.
Renal: 70–80% as unchanged drug; fecal: 10–20% via biliary elimination; minimal hepatic metabolism.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic